ES2630309T3 - Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos - Google Patents
Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos Download PDFInfo
- Publication number
- ES2630309T3 ES2630309T3 ES12846788T ES12846788T ES2630309T3 ES 2630309 T3 ES2630309 T3 ES 2630309T3 ES 12846788 T ES12846788 T ES 12846788T ES 12846788 T ES12846788 T ES 12846788T ES 2630309 T3 ES2630309 T3 ES 2630309T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- group
- c18aryl
- c12alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Compuesto de fórmula (I):**Fórmula** en la que: cada R1 y R1a se selecciona de forma independiente a partir del grupo formado por H, metilo, CONHC(CH3)3, OH, CO2H, CO2CH3, CO2CH2CH3, fenilo, CH2OH, CN y OCH3. o cualesquiera de dos R1 en átomos de carbono adyacentes pueden unirse para formar un radical cíclico, o cualesquiera de dos R1 del mismo carbono pueden formar, cuando se unen, un grupo de fórmula >=O Ar es un grupo C1-C18heteroarilo opcionalmente sustituido, seleccionado a partir del grupo formado por:**Fórmula** en el que cada R7 se selecciona de forma independiente a partir del grupo formado por H, halógeno, OH, NO2, CN, SH, NH2, CF3, OCF3, C1-C12alquilo opcionalmente sustituido, C1-C12haloalquilo opcionalmente sustituido, C2-C12alquenilo opcionalmente sustituido, C2-C12alquinilo opcionalmente sustituido, C2- C12heteroalquilo opcionalmente sustituido, C3-C12cicloalquilo opcionalmente sustituido, C3-C12cicloalquenilo opcionalmente sustituido, C2-C12heterocicloalquilo opcionalmente sustituido, C2-C12heterocicloalquenilo opcionalmente sustituido, C6-C18arilo opcionalmente sustituido, C1-C18heteroarilo opcionalmente sustituido, C1-C12alquiloxi opcionalmente sustituido, C2-C12alqueniloxi opcionalmente sustituido, C2-C12alquiniloxi opcionalmente sustituido, C2-C10heteroalquiloxi opcionalmente sustituido, C3-C12cicloalquiloxi opcionalmente sustituido, C3-C12cicloalqueniloxi opcionalmente sustituido, C2-C12heterocicloalquiloxi opcionalmente sustituido, C2-C12 heterocicloalqueniloxi opcionalmente sustituido, C6-C18ariloxi opcionalmente sustituido, C1-C18 heteroariloxi opcionalmente sustituido, C1-C12alquilamino opcionalmente sustituido, SR9, SO3H, SO2NR9R10, SO2R9, SONR9R10, SOR9, COR9, COOH, COOR9, CONR9R10, NR9COR10, NR9COOR10, NR9SO2R10, NR9CONR9R10, NR9R10 y acilo; en el que R8 se selecciona a partir del grupo formado por H, C1-C12alquilo opcionalmente sustituido, C2- C12alquenilo opcionalmente sustituido, C2-C12alquinilo opcionalmente sustituido, C2-C12heteroalquilo opcionalmente sustituido, C3-C12cicloalquilo opcionalmente sustituido, C2-C12heterocicloalquilo opcionalmente sustituido, C6-C18arilo opcionalmente sustituido, C1-C18heteroarilo opcionalmente sustituido, SO3H, SO2NR9R10, SO2R9, SONR9R10, SOR9, COR9, COOH, COOR9 y CONR9R10; en el que cada R9 y R10 se selecciona de forma independiente a partir del grupo formado por H, C1- C12alquilo opcionalmente sustituido, C2-C10heteroalquilo opcionalmente sustituido, C1-C12haloalquilo opcionalmente sustituido, C3-C12cicloalquilo opcionalmente sustituido, C6-C18arilo opcionalmente sustituido y C1-C18heteroarilo opcionalmente sustituido. e es un número entero seleccionado a partir del grupo formado por 0, 1, 2, 3 y 4; f es un número entero seleccionado a partir del grupo formado por 0, 1, 2 y 3; A es -CRaRb-; B es un grupo de fórmula -(CRcRd)n-; en el que cada Ra, Rb, Rc y Rd se selecciona de forma independiente a partir del grupo formado por H, halógeno, OH, NO2, CN, SH, NH2, CF3, OCF3, C1-C12alquilo, C2-C10heteroalquilo, C1-C12haloalquilo, C3- C12cicloalquilo, C6-C18arilo, C1-C18heteroarilo; SR2, SO3H, SO2NR2R3, SO2R2, SONR2R3, SOR2, COR2, COOH, COOR2, CONR2R3, NR2COR3, NR2COOR3, NR2SO2R3, NR2CONR2R2, NR2R3 y acilo, en el que cada R2 y R3 se selecciona de forma independiente a partir del grupo formado por H, C1- C12alquilo, C2-C10heteroalquilo, C1-C12haloalquilo, C3-C12cicloalquilo, C6-C18arilo y C1-C18heteroarilo; W1 y W2 se seleccionan de modo que uno es N y el otro es (CR12), el enlace del carbono carbonílico se forma con cualquiera de W1 o W2 que sea N, D es O o (CR12), n es un número entero seleccionado a partir del grupo formado por 0, 1 y 2; a es un número entero seleccionado a partir del grupo formado por 0, 1 y 2, 3; b es un número entero seleccionado a partir del grupo formado por 0, 1, 2, 3, 4, 5, 6, 7 y 8, c es 1; o una sal del mismo, aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4527CH2011 | 2011-12-22 | ||
PCT/IN2012/000841 WO2013128465A1 (en) | 2011-12-22 | 2012-12-21 | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2630309T3 true ES2630309T3 (es) | 2017-08-21 |
Family
ID=54258979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12846788T Active ES2630309T3 (es) | 2011-12-22 | 2012-12-21 | Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos |
Country Status (21)
Country | Link |
---|---|
US (1) | US9453014B2 (es) |
EP (1) | EP2800748B1 (es) |
JP (1) | JP6118340B2 (es) |
KR (1) | KR102083040B1 (es) |
CN (1) | CN104125956B (es) |
AU (1) | AU2012372019B2 (es) |
BR (1) | BR112014015301A8 (es) |
CA (1) | CA2860187C (es) |
CL (1) | CL2014001704A1 (es) |
CO (1) | CO7160013A2 (es) |
DK (1) | DK2800748T3 (es) |
ES (1) | ES2630309T3 (es) |
IL (1) | IL233270A0 (es) |
MA (1) | MA35874B1 (es) |
MX (1) | MX354361B (es) |
MY (1) | MY173696A (es) |
PH (1) | PH12014501442A1 (es) |
RU (1) | RU2669695C2 (es) |
SG (1) | SG11201403268QA (es) |
WO (1) | WO2013128465A1 (es) |
ZA (1) | ZA201405263B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9382424B2 (en) * | 2011-09-26 | 2016-07-05 | Nitto Denko Corporation | Highly-fluorescent and photo-stable chromophores for enhanced solar harvesting efficiency |
JP2013084952A (ja) | 2011-10-05 | 2013-05-09 | Nitto Denko Corp | 太陽光捕集効率を向上させるための、感圧接着剤層を含む波長変換膜 |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CN106397377B (zh) * | 2016-09-05 | 2019-04-05 | 中南大学 | 一种富电子五元杂环酸及其衍生物脱羧上氟的方法 |
KR102440809B1 (ko) | 2017-02-24 | 2022-09-05 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법 |
US11312714B2 (en) | 2017-06-30 | 2022-04-26 | The Regents Of The University Of California | Compositions and methods for modulating hair growth |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005501B1 (de) * | 1978-05-20 | 1981-11-25 | Bayer Ag | Heteroaryl-oxyessigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide |
DE2903966A1 (de) * | 1979-02-02 | 1980-08-07 | Bayer Ag | Substituierte carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
EP0336356A3 (en) * | 1988-04-05 | 1991-09-25 | Abbott Laboratories | Derivatives of tryptophan as cck antagonists |
FR2703679B1 (fr) | 1993-04-05 | 1995-06-23 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
FR2777566B1 (fr) * | 1998-04-15 | 2003-02-21 | Synthelabo | Derives d'azacycloalcanes, leur preparation et leur application en therapeutique |
EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | isoxazole |
EP2239012A3 (en) * | 2003-04-11 | 2011-06-15 | High Point Pharmaceuticals, LLC | Substituted amide derivatives and pharmaceutical uses thereof |
DE102004005172A1 (de) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
US20050239853A1 (en) * | 2004-02-04 | 2005-10-27 | Tjeerd Barf | New compounds |
EP1773771A2 (en) * | 2004-07-23 | 2007-04-18 | Daiamed, Inc. | Compounds and methods for treatment of thrombosis |
US8586748B2 (en) * | 2008-04-09 | 2013-11-19 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 |
ES2350077B1 (es) * | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
-
2012
- 2012-12-21 CA CA2860187A patent/CA2860187C/en not_active Expired - Fee Related
- 2012-12-21 US US14/367,614 patent/US9453014B2/en active Active
- 2012-12-21 SG SG11201403268QA patent/SG11201403268QA/en unknown
- 2012-12-21 JP JP2014548339A patent/JP6118340B2/ja not_active Expired - Fee Related
- 2012-12-21 AU AU2012372019A patent/AU2012372019B2/en not_active Ceased
- 2012-12-21 RU RU2014126646A patent/RU2669695C2/ru active
- 2012-12-21 EP EP12846788.3A patent/EP2800748B1/en not_active Not-in-force
- 2012-12-21 WO PCT/IN2012/000841 patent/WO2013128465A1/en active Application Filing
- 2012-12-21 MY MYPI2014001836A patent/MY173696A/en unknown
- 2012-12-21 MX MX2014007719A patent/MX354361B/es active IP Right Grant
- 2012-12-21 BR BR112014015301A patent/BR112014015301A8/pt not_active IP Right Cessation
- 2012-12-21 ES ES12846788T patent/ES2630309T3/es active Active
- 2012-12-21 KR KR1020147020455A patent/KR102083040B1/ko active IP Right Grant
- 2012-12-21 CN CN201280070441.8A patent/CN104125956B/zh not_active Expired - Fee Related
- 2012-12-21 DK DK12846788.3T patent/DK2800748T3/en active
-
2014
- 2014-06-19 IL IL233270A patent/IL233270A0/en unknown
- 2014-06-20 PH PH12014501442A patent/PH12014501442A1/en unknown
- 2014-06-23 CL CL2014001704A patent/CL2014001704A1/es unknown
- 2014-07-18 ZA ZA2014/05263A patent/ZA201405263B/en unknown
- 2014-07-20 MA MA37227A patent/MA35874B1/fr unknown
- 2014-07-22 CO CO14158010A patent/CO7160013A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP6118340B2 (ja) | 2017-04-19 |
RU2669695C2 (ru) | 2018-10-15 |
MX2014007719A (es) | 2015-03-19 |
AU2012372019A1 (en) | 2014-07-24 |
RU2014126646A (ru) | 2016-02-10 |
NZ626745A (en) | 2016-06-24 |
ZA201405263B (en) | 2016-05-25 |
KR102083040B1 (ko) | 2020-02-28 |
US20150158860A1 (en) | 2015-06-11 |
BR112014015301A2 (pt) | 2017-06-13 |
CN104125956A (zh) | 2014-10-29 |
SG11201403268QA (en) | 2014-07-30 |
EP2800748A1 (en) | 2014-11-12 |
MY173696A (en) | 2020-02-17 |
CN104125956B (zh) | 2019-08-16 |
WO2013128465A1 (en) | 2013-09-06 |
JP2015521154A (ja) | 2015-07-27 |
PH12014501442B1 (en) | 2014-10-08 |
KR20140127226A (ko) | 2014-11-03 |
BR112014015301A8 (pt) | 2017-07-04 |
CO7160013A2 (es) | 2015-01-15 |
MA35874B1 (fr) | 2014-12-01 |
CA2860187A1 (en) | 2013-09-06 |
IL233270A0 (en) | 2014-08-31 |
MX354361B (es) | 2018-02-28 |
DK2800748T3 (en) | 2017-07-17 |
AU2012372019B2 (en) | 2017-06-15 |
CA2860187C (en) | 2020-11-10 |
US9453014B2 (en) | 2016-09-27 |
CL2014001704A1 (es) | 2015-03-13 |
PH12014501442A1 (en) | 2014-10-08 |
EP2800748B1 (en) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2630309T3 (es) | Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos | |
NI201400099A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
CY1120780T1 (el) | Μακροκυκλικοι αναστολεις πρωτεασης σερινης της ηπατιτιδας c | |
CR20120418A (es) | Inhibidores de virus flaviviridae | |
NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
PE20150862A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR123089A2 (es) | Compuesto de piridinona | |
AR090044A1 (es) | Agentes antivirales para la hepatitis b | |
CO7240410A2 (es) | Inhibidores macrocíclicos de virus flaviviridae | |
AR088092A1 (es) | Procesos para preparar inhibidores de quinasas atr utiles para el tratamiento del cancer | |
AR087453A1 (es) | Composiciones de combustible | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
GT201200346A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
CO6150135A2 (es) | Bencilaminas un proceso para su produccion y su uso como agentes antiinflamatorios | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
AR123783A2 (es) | Dispersión sólida amorfa que comprende un derivado de tetrazol y composición farmacéutica que comprende dicha dispersión | |
AR090041A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de mgat2 | |
ES2577382T3 (es) | Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos | |
ES2602075T3 (es) | Profármacos de agentes antiinflamatorios no esteroideos (AINE) | |
AR083579A1 (es) | Inhibidor de cetp de oxazodilinona sustituida con amina ciclica | |
AR078164A1 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden | |
AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
AR093797A1 (es) | Derivados de feniletilpiridina inhibidores de pde-4 | |
AR099132A1 (es) | Colorante-polímero |